FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579276148> ?p ?o ?g. }

• W2579276148 endingPage "4434" @default.
• W2579276148 startingPage "4434" @default.
• W2579276148 abstract "Abstract Altered DNA repair mechanisms are responsible for survival of leukemia stem cells (LSCs) and/or leukemia progenitor cells (LPCs) accumulating numerous lethal DNA double-strand breaks (DSBs). DSBs resulting from stalled/broken replication forks in proliferating cells are primarily repaired by RAD51-mediated homologous recombination repair (HR), which depends on BRCA1-PALB2-BRCA2-RAD51 paralogs (BRCA pathway), while RAD52 pathway serves as redundant back-up mechanism. Enhanced self-renewal of LSCs and high proliferation rate of LPCs commit them to HR. It has been reported that inhibition of RAD52 either by the knockout, specific shRNA, or a small peptide aptamer induced synthetic lethality in BRCA pathway-deficient tumor cell lines and primary leukemia cells. Yet pharmacological inhibition of RAD52, which binds single-stranded DNA (ssDNA) and lacks enzymatic activity, has not been demonstrated. Here, we applied high-throughput screening and structure-based selection followed by biochemical assays and computer modeling to identify three leading compounds: (1) 20264, (2) RU-0084339, and (3) D-I03. Compound 20264 appeared to interact with the hotspot in RAD52 DNA binding domain 1 to interfere with ssDNA binding. RU-0084339 is a major allosteric inhibitor of RAD52 ssDNA binding domain which disassembles undecamer ring structure of RAD52. D-I03 abrogated RAD52-mediated ssDNA annealing and ssDNA pairing. RAD52 small molecule inhibitor (RAD52smi) reduced recruitment of RAD52 to DNA damage-induced nuclear foci and suppressed RAD52-mediated DNA double-strand break (DSB) repair activity in cells with negligible effects on other DSB repair pathways. Importantly, RAD52smi selectively eliminated cancer cell lines carrying BRCA1/2 inactivating mutations. Since inactivating mutations in BRCA pathway are rare in leukemias, individual BRCA pathway-deficient leukemias were identified by Gene Expression and Mutation Analysis (GEMA). Gene Expression approach applied microarrays, qRT-PCR, and/or flow cytometry to identify individual leukemias displaying downregulation of at least one gene in BRCA pathway. On the other hand, Gene Mutation strategy detected individual leukemias expressing an oncogene causing downregulation of BRCA pathway gene(s) (e.g., BCR-ABL1, MLL-AF9, AML1-ETO - mediated downregulation of BRCA1 and/or BRCA2) and harboring inactivating mutations in BRCA pathway (e.g., BRCA2 = FANCD1, and other FA genes). BRCA-deficient cells from individual patients indentified by GEMA were selectively sensitive to RAD52smi alone or in combination with already approved cytotoxic drugs. RAD52 is a promising new target because it is druggable by small molecule inhibitors. Moreover, inhibition of RAD52 by genetic knockout and small peptide aptamer did not exert any major negative effects in normal cells and tissues. Altogether, this work provided foundation for precision medicine guided synthetic lethality in BRCA-deficient leukemias exerted by small molecule inhibitors targeting novel mechanism - RAD52 dependent DSB repair. Disclosures No relevant conflicts of interest to declare." @default.
• W2579276148 created "2017-01-26" @default.
• W2579276148 creator A5006700695 @default.
• W2579276148 creator A5010225632 @default.
• W2579276148 creator A5026994096 @default.
• W2579276148 creator A5032397825 @default.
• W2579276148 creator A5032459319 @default.
• W2579276148 creator A5045784849 @default.
• W2579276148 creator A5049450086 @default.
• W2579276148 creator A5063022331 @default.
• W2579276148 creator A5071817184 @default.
• W2579276148 creator A5080315304 @default.
• W2579276148 creator A5082223399 @default.
• W2579276148 date "2015-12-03" @default.
• W2579276148 modified "2023-09-30" @default.
• W2579276148 title "Identification of a Small Molecule Inhibitor of RAD52 to Induce Synthetic Lethality in BRCA-Deficient Leukemias" @default.
• W2579276148 doi "https://doi.org/10.1182/blood.v126.23.4434.4434" @default.
• W2579276148 hasPublicationYear "2015" @default.
• W2579276148 type Work @default.
• W2579276148 sameAs 2579276148 @default.
• W2579276148 citedByCount "1" @default.
• W2579276148 countsByYear W25792761482017 @default.
• W2579276148 crossrefType "journal-article" @default.
• W2579276148 hasAuthorship W2579276148A5006700695 @default.
• W2579276148 hasAuthorship W2579276148A5010225632 @default.
• W2579276148 hasAuthorship W2579276148A5026994096 @default.
• W2579276148 hasAuthorship W2579276148A5032397825 @default.
• W2579276148 hasAuthorship W2579276148A5032459319 @default.
• W2579276148 hasAuthorship W2579276148A5045784849 @default.
• W2579276148 hasAuthorship W2579276148A5049450086 @default.
• W2579276148 hasAuthorship W2579276148A5063022331 @default.
• W2579276148 hasAuthorship W2579276148A5071817184 @default.
• W2579276148 hasAuthorship W2579276148A5080315304 @default.
• W2579276148 hasAuthorship W2579276148A5082223399 @default.
• W2579276148 hasConcept C102744134 @default.
• W2579276148 hasConcept C134935766 @default.
• W2579276148 hasConcept C143425029 @default.
• W2579276148 hasConcept C153911025 @default.
• W2579276148 hasConcept C2776630724 @default.
• W2579276148 hasConcept C2778502085 @default.
• W2579276148 hasConcept C2779012473 @default.
• W2579276148 hasConcept C54355233 @default.
• W2579276148 hasConcept C552990157 @default.
• W2579276148 hasConcept C86803240 @default.
• W2579276148 hasConcept C95444343 @default.
• W2579276148 hasConceptScore W2579276148C102744134 @default.
• W2579276148 hasConceptScore W2579276148C134935766 @default.
• W2579276148 hasConceptScore W2579276148C143425029 @default.
• W2579276148 hasConceptScore W2579276148C153911025 @default.
• W2579276148 hasConceptScore W2579276148C2776630724 @default.
• W2579276148 hasConceptScore W2579276148C2778502085 @default.
• W2579276148 hasConceptScore W2579276148C2779012473 @default.
• W2579276148 hasConceptScore W2579276148C54355233 @default.
• W2579276148 hasConceptScore W2579276148C552990157 @default.
• W2579276148 hasConceptScore W2579276148C86803240 @default.
• W2579276148 hasConceptScore W2579276148C95444343 @default.
• W2579276148 hasIssue "23" @default.
• W2579276148 hasLocation W25792761481 @default.
• W2579276148 hasOpenAccess W2579276148 @default.
• W2579276148 hasPrimaryLocation W25792761481 @default.
• W2579276148 hasRelatedWork W1975103548 @default.
• W2579276148 hasRelatedWork W2014091491 @default.
• W2579276148 hasRelatedWork W2036180332 @default.
• W2579276148 hasRelatedWork W2075114159 @default.
• W2579276148 hasRelatedWork W2093318486 @default.
• W2579276148 hasRelatedWork W2115797273 @default.
• W2579276148 hasRelatedWork W2125819717 @default.
• W2579276148 hasRelatedWork W2129634719 @default.
• W2579276148 hasRelatedWork W2158307844 @default.
• W2579276148 hasRelatedWork W2173350709 @default.
• W2579276148 hasRelatedWork W2553573182 @default.
• W2579276148 hasRelatedWork W2594301310 @default.
• W2579276148 hasRelatedWork W2787259960 @default.
• W2579276148 hasRelatedWork W2796207984 @default.
• W2579276148 hasRelatedWork W2803487838 @default.
• W2579276148 hasRelatedWork W2807806217 @default.
• W2579276148 hasRelatedWork W2906423617 @default.
• W2579276148 hasRelatedWork W3136315141 @default.
• W2579276148 hasRelatedWork W3169718874 @default.
• W2579276148 hasRelatedWork W1577338910 @default.
• W2579276148 hasVolume "126" @default.
• W2579276148 isParatext "false" @default.
• W2579276148 isRetracted "false" @default.
• W2579276148 magId "2579276148" @default.
• W2579276148 workType "article" @default.